Elevated eosinophil-to-lymphocyte ratio (ELR) as a predictor of relapse for IgG4-related disease: a retrospective study across a decade
Authors:
Open Access
- 9 June 2025
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-11
Abstract
To investigate the clinical significance of leukocyte-to-lymphocyte ratios, particularly the eosinophil-to-lymphocyte ratio (ELR) and basophil-to-lymphocyte ratio (BLR), in IgG4-related disease (IgG4-RD). We enrolled 541 treatment-naïve IgG4-RD patients and compared their ELR, BLR, neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR) with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and primary Sjögren’s syndrome (pSS) patients. K-means cluster analysis was performed to categorize enrolled IgG4-RD patients based on inflammatory markers (ELR, BLR, NLR, Complement 3, Complement 4, erythrocyte sedimentation rate), and clinical data of different clusters were analyzed using statistical methods including Kaplan–Meier curves and Cox regression. ELR and BLR levels were significantly elevated in IgG4-RD patients (ELR: 0.11 [0.05–0.22]; BLR: 0.02 [0.01–0.03]) compared to SLE, RA, and pSS patients (all P < 0.001). ELR was strongly associated with higher disease activity, increased serum IgG4, the number of affected organs, and proliferative phenotype proportions in IgG4-RD patients. We identified a high-risk subgroup of IgG4-RD patients with high ELR/BLR and low complement 3/4 (C3/C4) through clustering analysis. This subgroup exhibited higher disease activity and relapse risk. And IgG4-RD patients with high ELR (≥ 0.1103) had higher relapse rates during follow-up (HR = 2.12, 95% CI 1.37–3.26, P = 0.0005). ELR was identified as a risk factor for relapse in IgG4-RD patients. Our study indicated that the significantly elevated ELR reflects Th2 immune dysregulation and disease severity in IgG4-RD and serves as an independent predictor of relapse, offering a potential biomarker for personalized management.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005, CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005)
- National High Level Hospital Clinical Research Funding ((2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013, (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013)
- Beijing Natural Science Foundation (7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113, 7232113)
- National Natural Science Foundation of China (82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829, 82271848, 823B2037, 82471829)
- National Key Research and Development Program of China (2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104, 2022YFC2703104)
This publication has 37 references indexed in Scilit:
- CD163+ M2 Macrophages Promote Fibrosis in IgG4‐Related Disease Via Toll‐like Receptor 7/Interleukin‐1 Receptor–Associated Kinase 4/NF‐κB SignalingArthritis & Rheumatology, 2022
- IgG4-related disease: an update on pathophysiology and implications for clinical careNature Reviews Rheumatology, 2020
- The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related DiseaseArthritis & Rheumatology, 2019
- Management of IgG4-related diseaseThe Lancet Rheumatology, 2019
- An International Multispecialty Validation Study of the IgG4‐Related Disease Responder IndexArthritis Care & Research, 2018
- Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related DiseaseClinical Gastroenterology and Hepatology, 2017
- Type 2 immunity in tissue repair and fibrosisNature Reviews Immunology, 2017
- 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient CohortsArthritis & Rheumatology, 2016
- Toll-like receptor activation in basophils contributes to the development of IgG4-related diseaseJournal of Gastroenterology, 2012
- IgE and mast cells in allergic diseaseNature Medicine, 2012